This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Argenx Bv. Active years: 2022-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2024
Title: The Innovations of Piotr Zabrocki
Introduction
Piotr Zabrocki is a notable inventor based in Zwijnaarde, Belgium. He has made significant contributions to the field of medical therapies, particularly in the treatment of malignancies. With a total of two patents to his name, his work focuses on innovative combination therapies that target specific cancer cells.
Latest Patents
Zabrocki's latest patents include advancements in CD70 combination therapy. This invention relates to combination therapies for the treatment of malignancy, especially myeloid malignancy such as acute myeloid leukemia (AML). The therapies may involve an antibody molecule that binds to CD70, along with at least one antibody molecule that targets leukemic stem cells. Preferred targets for these therapies include TIM-3, IL1R3/IL1RAP, and CD47.
Career Highlights
Throughout his career, Piotr Zabrocki has worked with prominent companies in the biotechnology sector, including Argenx BV and Argenx BVBA. His experience in these organizations has allowed him to develop and refine his innovative approaches to cancer treatment.
Collaborations
Zabrocki has collaborated with several professionals in his field, including Luc Van Rompaey and Mahan Moshir. These collaborations have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Piotr Zabrocki's contributions to the field of cancer treatment through his innovative patents highlight his dedication to improving patient outcomes. His work continues to influence the development of effective therapies for malignancies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile